Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.
Identifieur interne : 001215 ( PubMed/Curation ); précédent : 001214; suivant : 001216Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.
Auteurs : Andrew R. Willan [Canada] ; Ron Goeree ; Eleanor M. Pullenayegum ; Christopher Mcburney ; Gordon BlackhouseSource :
- PharmacoEconomics [ 1170-7690 ] ; 2006.
Descripteurs français
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Aged, Canada, Cost-Benefit Analysis, Dementia (drug therapy), Dementia (economics), Female, Humans, Male, Middle Aged, Multicenter Studies as Topic, Neuroprotective Agents (economics), Neuroprotective Agents (therapeutic use), Parkinson Disease, Phenylcarbamates (economics), Phenylcarbamates (therapeutic use), Randomized Controlled Trials as Topic, Rivastigmine.
- MESH :
- chemical , economics : Neuroprotective Agents, Phenylcarbamates.
- chemical , therapeutic use : Neuroprotective Agents, Phenylcarbamates.
- geographic : Canada, Rivastigmine.
- drug therapy : Dementia.
- economics : Dementia.
- Aged, Cost-Benefit Analysis, Female, Humans, Male, Middle Aged, Multicenter Studies as Topic, Parkinson Disease, Randomized Controlled Trials as Topic.
Abstract
The positive results of a randomised clinical trial of rivastigmine in patients with dementia associated with Parkinson's disease have been published recently. Patient-level healthcare utilisation data were also collected, and this report is the economic evaluation based on these data.
PubMed: 16445306
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001215
Links to Exploration step
pubmed:16445306Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.</title><author><name sortKey="Willan, Andrew R" sort="Willan, Andrew R" uniqKey="Willan A" first="Andrew R" last="Willan">Andrew R. Willan</name><affiliation wicri:level="1"><nlm:affiliation>SickKids Research Institute and Department of Public Health Sciences, Programme in Public Health Sciences, University of Toronto, Toronto, Ontario, Canada. andy@andywillan.com</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>SickKids Research Institute and Department of Public Health Sciences, Programme in Public Health Sciences, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Goeree, Ron" sort="Goeree, Ron" uniqKey="Goeree R" first="Ron" last="Goeree">Ron Goeree</name></author><author><name sortKey="Pullenayegum, Eleanor M" sort="Pullenayegum, Eleanor M" uniqKey="Pullenayegum E" first="Eleanor M" last="Pullenayegum">Eleanor M. Pullenayegum</name></author><author><name sortKey="Mcburney, Christopher" sort="Mcburney, Christopher" uniqKey="Mcburney C" first="Christopher" last="Mcburney">Christopher Mcburney</name></author><author><name sortKey="Blackhouse, Gordon" sort="Blackhouse, Gordon" uniqKey="Blackhouse G" first="Gordon" last="Blackhouse">Gordon Blackhouse</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16445306</idno><idno type="pmid">16445306</idno><idno type="wicri:Area/PubMed/Corpus">001215</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001215</idno><idno type="wicri:Area/PubMed/Curation">001215</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001215</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.</title><author><name sortKey="Willan, Andrew R" sort="Willan, Andrew R" uniqKey="Willan A" first="Andrew R" last="Willan">Andrew R. Willan</name><affiliation wicri:level="1"><nlm:affiliation>SickKids Research Institute and Department of Public Health Sciences, Programme in Public Health Sciences, University of Toronto, Toronto, Ontario, Canada. andy@andywillan.com</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>SickKids Research Institute and Department of Public Health Sciences, Programme in Public Health Sciences, University of Toronto, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Goeree, Ron" sort="Goeree, Ron" uniqKey="Goeree R" first="Ron" last="Goeree">Ron Goeree</name></author><author><name sortKey="Pullenayegum, Eleanor M" sort="Pullenayegum, Eleanor M" uniqKey="Pullenayegum E" first="Eleanor M" last="Pullenayegum">Eleanor M. Pullenayegum</name></author><author><name sortKey="Mcburney, Christopher" sort="Mcburney, Christopher" uniqKey="Mcburney C" first="Christopher" last="Mcburney">Christopher Mcburney</name></author><author><name sortKey="Blackhouse, Gordon" sort="Blackhouse, Gordon" uniqKey="Blackhouse G" first="Gordon" last="Blackhouse">Gordon Blackhouse</name></author></analytic><series><title level="j">PharmacoEconomics</title><idno type="ISSN">1170-7690</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Canada</term><term>Cost-Benefit Analysis</term><term>Dementia (drug therapy)</term><term>Dementia (economics)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Multicenter Studies as Topic</term><term>Neuroprotective Agents (economics)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease</term><term>Phenylcarbamates (economics)</term><term>Phenylcarbamates (therapeutic use)</term><term>Randomized Controlled Trials as Topic</term><term>Rivastigmine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Neuroprotective Agents</term><term>Phenylcarbamates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Phenylcarbamates</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term><term>Rivastigmine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Dementia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cost-Benefit Analysis</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Multicenter Studies as Topic</term><term>Parkinson Disease</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The positive results of a randomised clinical trial of rivastigmine in patients with dementia associated with Parkinson's disease have been published recently. Patient-level healthcare utilisation data were also collected, and this report is the economic evaluation based on these data.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16445306</PMID><DateCreated><Year>2006</Year><Month>01</Month><Day>31</Day></DateCreated><DateCompleted><Year>2006</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1170-7690</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>PharmacoEconomics</Title><ISOAbbreviation>Pharmacoeconomics</ISOAbbreviation></Journal><ArticleTitle>Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.</ArticleTitle><Pagination><MedlinePgn>93-106</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The positive results of a randomised clinical trial of rivastigmine in patients with dementia associated with Parkinson's disease have been published recently. Patient-level healthcare utilisation data were also collected, and this report is the economic evaluation based on these data.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the cost effectiveness of rivastigmine 3-12 mg/day in patients in whom mild to moderate dementia developed at least 2 years after they received a clinical diagnosis of Parkinson's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cost-effectiveness analysis was performed by applying Canadian and UK cost weights (year 2004 values) to healthcare utilisation data collected prospectively during a randomised, double-blind, multinational, 24-week trial of rivastigmine 3-12 mg/day (n = 362) versus placebo (n = 179). Patients were > or =50 years of age, had a Mini-Mental State Examination (MMSE) score of between 20 and 24 and had contact with a responsible caregiver at least 3 days a week.Quality-adjusted survival time, transformed from MMSE scores, was the measure of effectiveness. Caregiver costs included paid and unpaid time, and direct costs included concomitant medications, outpatient care, hospitalisations, long-term care and study medications. Analysis was conducted from a societal perspective with a time horizon of 24 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Consistent with the improvement in clinical outcomes, there was an observed increase in quality-adjusted survival time in the rivastigmine arm of 2.81 quality-adjusted life-days (two-sided p-value 0.13 [90% CI -0.243, 5.86]). Using Canadian price weights, there was an observed increase in cost in the rivastigmine arm of Can 55.76 dollars(two-sided p-value 0.98 [90% CI -3431, 3543]), with a resulting incremental cost-effectiveness ratio of Can 7429 dollars per QALY. Using UK price weights, there was an observed decrease in cost in the rivastigmine arm of pound 26.18 (two-sided p-value 0.99 [90% CI -2407, 2355]).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although no between-treatment differences in cost were seen, the small sample size, highly variable cost distributions and short time horizon prevent us from making strong conclusions with regard to the effect of rivastigmine on total costs and, by inference, on cost effectiveness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willan</LastName><ForeName>Andrew R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>SickKids Research Institute and Department of Public Health Sciences, Programme in Public Health Sciences, University of Toronto, Toronto, Ontario, Canada. andy@andywillan.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goeree</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pullenayegum</LastName><ForeName>Eleanor M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>McBurney</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Blackhouse</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Pharmacoeconomics</MedlineTA><NlmUniqueID>9212404</NlmUniqueID><ISSNLinking>1170-7690</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>T</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16445306</ArticleId><ArticleId IdType="pii">2418</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001215 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001215 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16445306
|texte= Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16445306" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |